ACARIZAX®(12 SQ-HDM SLIT) becomes first-in-class treatment approved by NICE for the treatment of allergic rhinitis disease caused by house dust mite allergy - BSACI

ACARIZAX®(12 SQ-HDM SLIT) becomes first-in-class treatment approved by NICE for the treatment of allergic rhinitis disease caused by house dust mite allergy

30 January 2025


ALK (ALKB:DC / OMX: ALK B) today announced that NICE has recommended ACARIZAX (12 SQ-HDM
SLIT, also known as ‘sublingual immunotherapy’) for the treatment of moderate to severe house
dust mite allergic rhinitis disease in people 12 to 65 years that is persistent despite symptom-relieving medicine. 12 SQ-HDM SLIT is the first treatment of its kind to be approved by NICE. This decision paves the way for patient access to this therapy through the NHS. Click here to read the press release.